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Abstract
Acute lung injury (ALI), including the ventilator-induced lung injury (VILI) and the more severe acute respiratory distress syndrome (ARDS), are common and complex inflammatory lung diseases potentially affected by various genetic and non-genetic factors. Using the candidate gene approach, genetic variants associated with immune response and inflammatory pathways have been identified and implicated in ALI. Since gene expression is an intermediate phenotype that resides between DNA sequence variation and higher level cellular or whole-body phenotypes, the illustration of gene expression regulatory networks could potentially enhance understanding of disease susceptibility and the development of inflammatory lung syndromes. MicroRNAs (miRNAs) have emerged as a novel class of gene regulators which play critical roles in complex diseases including ALI. Comparisons of global miRNA profiles in animal models of ALI and VILI identified several miRNAs (e.g., miR-146a, miR-155) previously implicated in immune response and inflammatory pathways. Therefore, via regulation of target genes in these biological processes and pathways, miRNAs potentially contribute to the development of ALI. While this line of inquiry exists at a nascent stage, miRNAs have the potential to be critical components of a comprehensive model for inflammatory lung disease built by a systems biology approach that integrates genetic, genomic, proteomic, epigenetic as well environmental stimuli information.
Given their particularly recognized role in regulation of immune and inflammatory responses, miRNAs also serve as novel therapeutic targets and biomarkers for ALI/ARDS or VILI, thus facilitating the realization of personalized medicine for individuals with acute inflammatory lung disease.
Introduction
Inflammatory lung disorders include a wide range of pulmonary diseases such as cystic fibrosis, asthma, emphysema, chronic bronchitis, and chronic obstructive pulmonary disease, all of which are characterized by increased leukocyte infiltration (e.g., neutrophils and monocytic cells) into lung tissues as the body's immune response to infection or injury. An important inflammatory lung disease of rapid onset is acute lung injury (ALI) and the more severe form of ALI, acute respiratory distress syndrome (ARDS). ALI is a diffuse, heterogeneous type of acute lung injury clinically characterized by progressive hypoxemia, reduced lung compliance, and intense inflammation in the lung tissues that results from either direct injury to the lung (e.g., pneumonia, thoracic trauma, smoke-related lung injury) (1, 2) or an indirect insult (e.g., pancreatitis) (2) . It is estimated that each year in the United States alone, there are ~190,000 cases of ALI, which are associated with ~75,000 deaths and ~3.6 million hospital days (2, 3) . The treatment of inflammatory lung diseases such as ALI has historically involved supportive care and occasionally use of anti-inflammatory medications, such as corticosteroids, and antibiotics (4) . In addition, mechanical ventilation, so critical to support of the critically ill patients with respiratory failure, is recognized to confer additional risk via excessive ventilator-delivered tidal volumes which may worsen preexisting lung injury via shear forces generated during regional delivery of high tidal volume ventilation or even directly induce lung injury in patients placed on mechanical ventilation in the absence of preexisting lung injury (VILI:
ventilator-induced lung injury) (5). Another major complication of mechanical ventilation is the development of ventilator-associated pneumonia with both gram-positive and gram-negative organisms also resulting in subsequent prominent systemic inflammatory response (6) . Previous studies have shown that induction of systemic inflammation with intravenous bacterial lipopolysaccharide (LPS) can cause a synergistic increase in lung injury in the setting of mechanical ventilation (7) (8) (9) .
Among the many unanswered questions regarding ALI and ARDS is the heterogeneous response of individuals to similar risk factors and diseases which can produce ALI. Neither ALI nor ARDS are specific disease processes themselves, but rather represent syndromes developed in a fraction of individuals that are exposed to risk conditions such as trauma, sepsis, and pneumonia which potentially induce ALI (10, 11) .
A few relationships are obvious, for example, an older patient with serious comorbidities is at greater mortality risk than a younger, healthier patient with the same illness In addition, some important clinical predictors for the development and/or mortality in ALI/ARDS have been identified, including the severity of disease measured by Acute Physiology and Chronic Health Evaluation III score (APACHE), trauma, corticosteroids before ARDS, and packed red blood cell transfusions (12). However, it is wellrecognized that despite similar exposures to potential ALI-inciting insults, only a small proportion of exposed individuals will ultimately develop these syndromes (11) and the clinical outcomes in patient with similar clinical characteristics may vary significantly from complete resolution to death. Furthermore, significant race and gender differences have also been reported in the annual ARDS mortality rate (11, 13) .
These observations have led to an important focus on the potential contribution of genetics, gene-gene and gene-environment interactions as a potential explanation for the disparities observed in ALI/ARDS patients (11) . This review will introduce the general strategies for identifying genes and genetic variants implicated in ALI, and particularly, the potential role of microRNAs (miRNAs) (Figure 1 ), a class of novel gene-regulators made of small non-coding RNA molecules, in the pathogenesis of ALI/ARDS and VILI.
A picture which is emerging is that miRNAs, through their functional effects on gene regulation, have the potential to regulate many aspects of physiological homeostasis homeostasis (14) , modulate the risk of common diseases and drive therapeutic responsiveness (15) . Table 1 shows a list of miRNAs recently reported to be implicated in several inflammatory lung diseases. It is anticipated that future miRNA studies will be an important complement to the current genetic, genomic, and proteomic studies in furthering our understanding of common complex diseases including inflammatory lung disorders such as ALI.
Identifying genes and genetic variants implicated in ALI
Studies on the genetic basis of ALI/ARDS and VILI have generally focused on a limited number of putative mechanistic functions in lung injury and/or inflammation (11, 16) (Figure 1 ). This has identified several well-defined candidate genes such as ACE (angiotensin converting enzyme) (17, 18) , SOD3 (extracellular superoxide dismutase) (19, 20) , SP-B (surfactant protein B) (21, 22) For example, the interest in the relationship between ACE and ARDS originated from the hypothesis that activation of the pulmonary renin-angiotensin system might impact the pathogenesis of ALI/ARDS by inducing apoptosis, altering vascular permeability, vascular tone, and endothelial/ epithelial survival (43). Studies using animal models further suggested that the inflammation and apoptosis in VILI is, at least in part, due to ACE-mediated angiotensin II production (44) ; and that the inhibition of ACE by captopril (an ACE inhibitor used for the treatment of hypertension and some types of congestive heart failure) may attenuate VILI through the reduction of inflammatory cytokines, inhibition of apoptosis (45) as well as decrease of PAI-1 (46), the elevated expression of which was found to be associated with poor clinical outcomes in both pediatric and adult ALI (47, 48) . Furthermore, polymorphisms associated with the gene expression patterns of ACE, PAI-1 and other candidate genes (e.g., VEGF, IL-10, SOD3, PBEF) as well as their relationships with lung pathophysiology or clinical characteristics (e.g., mortality) have been identified (11, 16 (49, 50) . More recently, comparisons of global gene expression were used to identify differentially expressed genes between cases and controls with the aims to identify more candidate genes in inflammatory lung disease. For example, using the Affymetrix oligonucleotide microarray platform and a canine model of VILI, differential expression levels of a significant number of genes were identified between lung apex/base regions as well as between gravitationally dependent/nondependent regions of the base with major functional groupings of differentially regulated genes including inflammation and immune responses, cell proliferation, adhesion, signaling, and apoptosis (51) . In addition to a number of commonly known ALI-associated genes (e.g., VEGF, THBS1), microarray analysis also revealed several novel genes not previously described in the context of ALI.
One such novel gene is PBEF that encodes pre-B-cell colony enhancing factor (also known as visfatin), which was subsequently found to be over-expressed in human bronchoalveolar lavage fluid and serum samples from patients with ALI and in cytokineor cyclic stretch-activated lung microvascular endothelium (16, 41, 52) , thus having the potential to be a novel biomarker in ALI (41) .
Gene expression variation and regulation
Gene expression itself is a complex and quantitative phenotype that is regulated by various genetic and non-genetic factors. The contribution of genetics, especially in the form of cis-or trans-acting single SNPs (i.e., eQTLs, expression quantitative trait loci) has been illustrated using human cell line models (53, 54) . For example, studies using the human lymphoblastoid cell line samples (LCLs) (e.g., the International HapMap Project 
MicroRNAs regulate gene expression
MicroRNAs are a family of small non-coding RNAs (21-25 nucleotides in length)
found in almost all metazoan genomes, including worms, flies, plants and mammals (69) .
So far, ~700 miRNAs have been identified experimentally or computationally in humans (70) (71) (72) . As the current cloning technology favors highly expressed miRNAs, more exhaustive cloning efforts may be needed to catalogue all miRNAs (estimated >800 in humans) (73) that must cover more tissue types and developmental stages. Besides cloning, computational prediction was used to identify miRNAs that share homologous sequences with closely related species (73) MiRNAs have been discovered to play important regulatory roles in gene expression (67) . At least for those with characterized gene targets, miRNAs have been found to negatively regulate gene expression at the post-transcriptional level (i.e., through translational repression and mRNA degradation) by binding to the 3' untranslated regions (3'UTRs) (75) , although the precise molecular mechanism still needs to be defined.
Furthermore, computational predictions of miRNA targets have revealed a variety of regulatory pathways that might be subject to miRNA-mediation regulation (76) . Therefore, the emerging picture is that miRNAs, through their roles in gene regulation, have the potential to regulate almost all aspects of physiological conditions including disease susceptibility, disease development as well as response to therapeutic treatments.
For example, miRNA alterations or signatures have been found to be involved in the initiation, progression or prognosis of various complex human diseases such as cancer (77) (78) (79) (80) , diabetes (81, 82) , and cardiovascular disease (83) (84) (85) (86) (87) .
In addition, a class of functional polymorphisms termed miRSNPs or miRNA polymorphisms were recently reported to be new players in miRNA-mediated gene regulation. The miRSNPs are defined as polymorphisms present at or near miRNA binding sites of functional genes as well as in the genes involved in miRNA biogenesis and in pri-, pre-and mature-miRNA sequences, thus affecting gene expression by interfering with miRNAs (88). For example, the expression of miR-24, a ubiquitously expressed miRNA that has p53-independent tumor suppressor activity, was found to be deregulated in human colorectal tumor through a target site polymorphism (89) . A polymorphism in one of miR-24's target genes, DHFR (dihydrofolate reductase), was also found to lead to methotrexate resistance (90). Therefore, detecting miRSNPs would be critical in the studies of molecular epidemiology and the realization of personalized medicine. In fact, a comprehensive analysis of the impact of SNPs and CNVs on human miRNAs and their regulatory genes demonstrated a significant number of SNPs and CNVs in pre-miRNAs and miRNA target genes (91).
MicroRNAs implicated in immune responses and ALI
MicroRNAs have been shown to be centrally involved in the regulation of immune system development, differentiation of B and T cells, proliferation of monocytes and neutrophils, antibody production, the release of inflammatory mediators (92), and certain inflammatory lung diseases (e.g., cystic fibrosis, asthma, and idiopathic pulmonary fibrosis) (Table 1) In addition, our recent work on PBEF, a candidate gene for ALI, using human pulmonary artery endothelial cells suggests that miR-374a and miR-568 may decrease endogenous PBEF expression under 24 hrs of LPS challenge (unpublished data), indicating the potential role of miRNAs in regulating these genes in related pathways.
Furthermore, we found that miR-516a-5p was down-regulated in human lung microvascular endothelial cells after under LPS and HMW-HA (high molecular weight hyaluronan) challenge for 24 hrs (unpublished data). Interestingly, miR-516a-5p may regulate BLNK (B-cell linker) (105), suggesting a putative role of miR-516a-5p in B-cell differentiation and immune response, thus may be implicated in ALI.
Although most studies concerning miRNAs and inflammatory lung disease have been related to LPS responses to date, using animal models of ALI or VILI, there has been efforts to directly identify miRNAs that are differentially expressed. To further understand the mechanisms by which shear forces or cyclic stretch is translated into vascular barrier disruption and inflammation in the development of VILI, the effect of high tidal ventilation (HTV) on lung miRNA expression was studied in a murine model of VILI (106) . The expression levels of 365 miRNAs were compared between HTVtreated mice and control mice using TaqMan miRNA microarrays (106) and miRNA expression found to be altered according to the length of HTV treatment, suggesting a direct inducing role of VILI on miRNA expression. For example, the expression levels of 13 miRNAs were decreased by at least 50% after 4 hours of HTV, and in 12 of these differential miRNAs, a decrease of at least 30% was apparent after only one hour of HTV (106) . Several of these miRNAs were known to be associated with regulation of inflammation (106) and suggest that miRNAs may play an important role in lung inflammation associated with VILI and thus provide a potentially novel therapeutic target for VILI. It should be noted that the alterations of miRNAs in VILI lungs could come from infiltrated cells. Therefore, further studies may be necessary to comprehensively evaluate these observations.
MicroRNAs as potential molecular therapies and biomarkers in ALI
Currently, although the annual ARDS mortality rate is very slowly declining (107) , given that ALI is a common disease (~200,000 cases annually in the United States) and a mortality rate that exceeds 35% (11), there are compelling reasons to further our mechanistic understanding of ALI/ARDS and VILI. With the accumulating evidence that changes in miRNA expression are associated with immune response, inflammation pathways, and the pathogenesis of inflammatory lung disease including ALI, the potential of targeting miRNAs as a novel therapeutic approach looks very promising. The main molecular alterations in miRNAs are represented by gene expression variation (67) .
Although gene expression variation produced by miRNAs are usually moderate, but the consequence could potentially affect a vast number of target genes (70) , which in turn may influence various physiological pathways. RNA inhibition technologies using miRNAs may be used to block mRNA production and/or function of disease-related genes. For example, miRNAs that are negatively associated with the expression of inflammation pathway genes could be used to avoid over-expression of cytokines to repress acute inflammatory response in patients under mechanical ventilation, thus helping prevent the occurrence of VILI. In addition, miRNAs that directly participate in the pathogenesis of ALI/ARDS or VILI could be targeted by antisense oligonucleotides (i.e., antagomirs) by taking advantage of the sequence structure of these small RNA molecules (108) .
The expression patterns of miRNAs are believed to be dynamic and reflect the changing intra-/extra-cellular environment and signals. Therefore, miRNAs could be attractive as potential biomarkers to represent the underlying pathophysiological processes in specific disease states or development stages. Moreover, miRNAs can be detected in a variety of sources, including tissue, blood and body fluids. Also, they are reasonably stable and appear to be resistant to differences in sample handling, which increases their appeal as practical biomarkers (109) . Recently, miRNAs were identified in serum and plasma as biomarkers for diagnosing and monitoring several diseases including cancer, cardiovascular diseases, rheumatic diseases (109) (110) (111) . Circulating miR-146a and miR-223 were found significantly reduced in septic patients compared between systemic inflammatory response syndrome patients and healthy controls (112).
Wang et al. showed that serum miR-146a and miR-223 might serve as new biomarkers for sepsis with high specificity and sensitivity (112) . In contrast, Vsilescu et al. reported that the expression of miR-150 correlated with the aggressiveness of sepsis, therefore, they suggested that miR-150 could be plasma prognostic marker in patients with sepsis (113) . With the expected advances in understanding the relationships between miRNAs and ALI/ARDS or VILI through genome-wide miRNA profiling, more miRNA biomarkers associated with immune response, inflammation pathways, disease development, and disease severity could be evaluated as a novel tool in the diagnosis and monitor for inflammatory lung disease.
Future perspectives
Gene expression, a quantitative and complex trait, has been extensively studied during the past few years, especially using the human cell line models and the HapMap genotypic data (53) . Genetic variants like SNPs and CNVs have been found to contribute substantially to gene expression variation (57) (58) (59) (60) (61) (62) (63) . Defining the roles of miRNAs in gene expression regulation, however, still have many important hurdles to cross. Before we could comprehensively understand the role of miRNAs in inflammatory lung disease, some basic research studies on their role in gene regulation (e.g., building a systematic and more reliable catalogue of miRNA gene targets) will prove to be critical and benefit the research community. For example, due to cost and efficiency, current miRNA target identification still relies largely on computational algorithms (e.g., miRanda used by the miRBase (71, 74) , TargetScan (114, 115) , PicTar (116) (60) (61) (62) (63) , studying the role of miRNAs in regulating population differences in gene expression would provide novel insights in health disparities such as the higher mortality rate in ALI (as well as sepsis) in African Americans and Hispanics in the United States (13) . Although socioeconomic status could significantly affect health disparities, notably, genes related to immune response to bacterial infection (e.g., genes in inflammatory pathways such as CCR7, chemokine receptor 7 and CXCR3, chemokine receptor 3) were found to be enriched among the differentially expressed genes between the cell lines derived from individuals of African and European ancestry (60, 119) .
Previous studies attempted to illustrate the contribution of SNPs and CNVs to populationlevel gene expression variation (60) (61) (62) (63) , similarly, it would be interesting to investigate the contribution of miRNAs to differential gene expression between populations as well, thus helping explain the observed racial difference in diseases including ALI. In addition, expression variation in some genes has also been observed between males and females using the cell line models (120, 121) . Although genetics does not appear to affect genderspecific gene expression as males and females have the same autosomal genetic background, the contribution of miRNAs to gender-specific gene expression has not yet been studied. Therefore, it would be important to illustrate the role of miRNAs in defining gender-specific gene expression for the purpose of understanding the gender differences in inflammatory lung disease (e.g., gender differences in ARDS mortality rate (13)).
Because of the early stage of research, the current studies on the relationships between miRNAs and ALI/ARDS and VILI have been largely relied on animal models.
No doubt, results derived from animal models can guide further investigations on patient samples and future translational research, the interpretation of these results, however, needs to be cautious as not all results from animal models are relevant to humans. Therefore, expanding the current studies to human cell lines, tissues and ultimately human subjects would provide direct evidence to the role of miRNAs in the development of inflammatory lung disease.
Since miRNA expression is believed to be a dynamic process in cells, future experimental techniques that may monitor the longitudinal changes of miRNAs in vitro or in vivo and their interactions with changing cellular environment could provide unprecedented picture of the critical role of miRNAs in gene regulation and disease development. Finally, to construct a most comprehensive model for complex diseases such as ALI presents the challenges for integrating all kinds of data on the phenotypes or traits (e.g., gene expression, SNPs, CNVs, DNA methylation). MiRNAs will be critical components in our complete understanding of the mechanism and genetic networks of inflammatory lung disease. Though with some promising evidence so far, before they can be applied in the daily management of ALI, the potential of miRNAs to be novel therapeutic targets as well as biomarkers for ALI should also be continuously investigated.
Conclusion
Through their intimate role in gene regulation, miRNAs are emerging to be critical in understanding the underlying gene networks of complex diseases as well as phenotypes such as individual response to therapeutic treatments (15) . Although at an earlier stage of investigation in ALI/ARDS and VILI relative to other common diseases including cancer, promising evidence on miRNAs' potentially critical role in disease susceptibility and progress of inflammatory lung disease has accumulated rapidly particularly in animal models. More basic research studies on miRNAs as well as the the genetic variation related to miRNAs in real patient populations could benefit the ultimate goal of personalized medical care for inflammatory lung disease. It is expected that studies on miRNAs will facilitate the construction of a comprehensive disease model for ALI/ARDS or VILI by applying a systems biology approach that aims to integrate genetic, genomic, epigenetic, and proteomic as well as environmental information. # COL16A1: collagen, type XVI, alpha 1; ELFN2: extracellular leucine-rich repeat and fibronectin type III domain containing 2; GSK-3ß: glycogen synthase kinase 3ß; HMGA2: high mobility group AT-hook 2; HLA-G: major histocompatibility complex, class I, G; IER5: immediate early response 5; IFNG: interferon, gamma; IL-10: interleukin 10; IL-12: interleukin 12; IL-13: interleukin 13; KGF: keratinocyte growth factor; OBF.1/BOB.1: Oct binding factor 1 or B-cell Oct binding protein 1; PCDH20: protocadherin 20; PGE2: prostaglandin E2; PHTF2: putative homeodomain transcription factor 2; PLCH2: phospholipase C, eta 2; RHOA: ras homolog gene family, member A; SMAD7: SMAD family, member 7; TOM1: target of myb1. 
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